Monoclonal antibodies in the management of ovarian cancer. A clinical perspective. (Q40875124)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8431896 AND SRC:MED&resulttype=core&format=json

12 October 2019

review article

1 reference

title

Monoclonal antibodies in the management of ovarian cancer. A clinical perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8431896 AND SRC:MED&resulttype=core&format=json

12 October 2019

1 reference

S C Rubin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8431896 AND SRC:MED&resulttype=core&format=json

12 October 2019

language of work or name

English

0 references

publication date

1 February 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8431896 AND SRC:MED&resulttype=core&format=json

12 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8431896 AND SRC:MED&resulttype=core&format=json

12 October 2019

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8431896 AND SRC:MED&resulttype=core&format=json

12 October 2019

issue

4 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8431896 AND SRC:MED&resulttype=core&format=json

12 October 2019

page(s)

1602-1612

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8431896 AND SRC:MED&resulttype=core&format=json

Continuous cultures of fused cells secreting antibody of predefined specificity

12 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Reactivity of a monoclonal antibody with human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

A spectrum of monoclonal antibodies reactive with human mammary tumor cells

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Monoclonal antibodies against human ovarian tumor associated antigen NB/70K: preparation and use in a radioimmunoassay for measuring NB/70K in serum

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Monoclonal Antibodies to Three Widely Distributed Human Cell Surface Antigens

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: Production and reaction with cells in culture

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Immunopathologic analysis of a panel of mouse monoclonal antibodies reacting with human ovarian carcinomas and other human tumors

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

CA 125 Serum Levels Correlated With Second-Look Operations Among Ovarian Cancer Patients

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses. Discrimination of benign from malignant disease

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

The value of preoperative serum CA 125 levels in patients with a pelvic mass

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

CA 125 in gynecologic practice

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Hereditary ovarian cancer. Heterogeneity in age at diagnosis

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Studies directed toward the use of antibodies as carriers of radioactivity for therapy

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Radioimmunodetection and radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

TARGETING OF IODINE-123-LABELLED TUMOUR-ASSOCIATED MONOCLONAL ANTIBODIES TO OVARIAN, BREAST, AND GASTROINTESTINAL TUMOURS

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Immunoscintigraphy using CA 125 antibodies in the management of ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Immunoscintigraphy with 131I-labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Primary diagnosis and follow-up of ovarian cancer: radioimmunoscintigraphy with iodine-131 labeled OC 125 monoclonal antibodies versus computed tomography and "second look"

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Radioimmunoscintigraphy using monoclonal antibodies to CEA, CA 19-9 and CA 125

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Second-look surgery in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Radioimmunoguided surgery using monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Phase I Study of an Anti-Breast Cancer Immunotoxin by Continuous Infusion: Report of a Targeted Toxic Effect Not Predicted by Animal Studies

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Heterogeneity of antigen expression in advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

A longitudinal study of antigen expression in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/CNCR.2820710427

7 January 2021

Identifiers

DOI

10.1002/CNCR.2820710427

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8431896 AND SRC:MED&resulttype=core&format=json

12 October 2019

1 reference